✦ LIBER ✦

Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function?

✍ Scribed by Lu, Christine Y.; Srasuebkul, Preeyaporn; Drew, Anna K.; Chen, Katie; Ward, Robyn L.; Pearson, Sallie-Anne

Book ID: 122611459
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 251 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2013.04.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiac Toxicity Monitoring for HER2-pos

Cardiac Toxicity Monitoring for HER2-positive Breast Cancer Patients Undergoing Trastuzumab Therapy: Are We Doing Enough?

✍ Gujral, D.M.; Lloyd, G.; Bhattacharyya, S. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Serum HER-2/neu and relative resistance

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Ha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

Positive spillover effects of prescribin

Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer

✍ Lu, C. Y.; Srasuebkul, P.; Drew, A. K.; Ward, R. L.; Pearson, S.-A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

2108 POSTER Cardiac safety of trastuzuma

2108 POSTER Cardiac safety of trastuzumab in combination with epirubicin/ cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer

✍ M. Untch; S. Tjulandin; W. Jonat; H. Meerpohl; M. Lichinitser; G.M. Manikhas; F. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Phase Ib Study of Buparlisib plus Trastu

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

✍ Saura, C.; Bendell, J.; Jerusalem, G.; Su, S.; Ru, Q.; De Buck, S.; Mills, D.; R 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 898 KB